curacle co.,ltd. (KOSDAQ:365270)

South Korea flag South Korea · Delayed Price · Currency is KRW
18,610
+1,150 (6.59%)
At close: Feb 27, 2026
134.68%
Market Cap 377.93B
Revenue (ttm) 1.14B
Net Income (ttm) -17.50B
Shares Out 21.30M
EPS (ttm) -1,217.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 453,554
Average Volume 731,874
Open 17,180
Previous Close 17,460
Day's Range 17,170 - 18,900
52-Week Range 3,600 - 18,900
Beta 2.17
RSI 73.85
Earnings Date n/a

About curacle co.,ltd.

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- β/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 365270
Full Company Profile

Financial Performance

In 2024, curacle co.,ltd.'s revenue was 1.63 billion, a decrease of -84.14% compared to the previous year's 10.29 billion. Losses were -14.89 billion, 28.5% more than in 2023.

Financial Statements

News

There is no news available yet.